Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 9/20 | 0.69 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.63 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.62 |
| ▸ | AMD1 | P17707 | 2/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.56 |
| ▸ | NNMT | P40261 | 1/20 | 0.54 |
| ▸ | AHCY | P23526 | 1/20 | 0.54 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129509 | 1.00 | DOT1L (0.69) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL17153201 | 0.93 | DOT1L (0.68) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL9970136 | 0.93 | DOT1L (0.68) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL19125218 | 0.92 | DOT1L (0.67) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL9970151 | 0.92 | DOT1L (0.82) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL15829367 | 0.92 | DOT1L (0.82) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL17153319 | 0.91 | DOT1L (0.66) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL9970139 | 0.91 | DOT1L (0.66) | DOT1LCARM1EZH2AMD1PRMT5 | |
| SCHEMBL9970335 | 0.89 | DOT1L (0.73) | DOT1LCARM1EZH2AMD1AHCY | |
| SCHEMBL9970160 | 0.88 | PI4KA (0.56) | DOT1LCARM1EZH2AMD1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9670463-B2 | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-9446064-B2 | Combination therapy for treating cancer | Epizyme, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2016-02-18 | — | — | US | disclosed |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140242046-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | Childern's Medical Center Corporation (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014100662-A1 | DOT1 L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014026198-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | DOT1L 1/4885CARM1 3/4885EZH2 8/4885 |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | DOT1L, ASH1L, CARM1 | DOT1L 1/4885CARM1 3/4885EZH2 6/4885 |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | DOT1L 4/4885CARM1 5/4885EZH2 7/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | DOT1L 13/4885CARM1 8/4885EZH2 11/4885 |
| US-20160045531-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | DOT1L 1/4885CARM1 3/4885EZH2 6/4885 |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | DOT1L 1/4885CARM1 2/4885EZH2 6/4885 |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | DOT1L 1/4885CARM1 2/4885EZH2 6/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | DOT1L 1/4885CARM1 3/4885EZH2 8/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | DOT1L 1/4885CARM1 3/4885EZH2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.